Consolidated Entities (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Apr. 20, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Consolidated Entities
Receivable from related parties		$ 82,402		$ 82,402		$ 79,427	[1]
Cash balance		413,147		413,147		278,096	[1]
Total revenue		78,946	$ 64,107	157,624	$ 119,290
Total assets		879,619		879,619		724,826	[1]
Total operating expenses		3,155	4,347	5,718	7,362
Revenue from collaborative arrangements with a related party
Consolidated Entities
Total revenue		10,000	0	10,000	0
Theravance Respiratory Company, LLC
Consolidated Entities
Receivable from related parties		25,600		25,600		$ 14,400
Cash balance		16,500		16,500
Total revenue		15,600	$ 9,800	31,800	$ 17,200
Total operating expenses		500		800
Theravance Respiratory Company, LLC | Revenue from collaborative arrangements with a related party | MABA program
Consolidated Entities
Total revenue		10,000		10,000
Pulmoquine Therapeutics, Inc.
Consolidated Entities
Percentage of outstanding shares acquired	90.90%
Total assets		4,900		4,900
Total operating expenses		$ 600		$ 600
Pulmoquine Therapeutics, Inc. | Series A preferred stock
Consolidated Entities
Number of shares to be purchased under the securities purchase agreement	5,808,550
Payments for acquire variable interest	$ 5,000

[1] Consolidated balance sheet as of December 31, 2019 has been derived from audited consolidated financial statements.